Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Neurogene in a report released on ...

Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for CorMedix in a research note issued on Tuesday, March 25th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post ...

Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former ...

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (NasdaqCM:EQ) from Outperform ...

Leerink analyst Thomas Smith downgraded Equillium (EQ) to Market Perform from Outperform with a price target of $1, down from $3. The company ...

In a report released on March 24, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The ...

Shares of Viking Therapeutics slid despite what analysts at brokerage Leerink Partners called "rapid" enrollment for the drug developer's widely anticipated obesity drug trial. Rival makers of ...

Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the ...

Fintel reports that on March 25, 2025, Leerink Partners downgraded their outlook for Opthea Limited - Depositary Receipt () ...

CVS Health saw a notable shift as Tocqueville Asset Management slashed its stake in the company by over 50% in Q4. Other ...